Marc Bellet Selected Research

aprocitentan

12/2022	Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
1/2022	Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
1/2020	Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Bellet Research Topics

Disease

4	Hypertension (High Blood Pressure) 12/2022 - 09/2010
1	Essential Hypertension 01/2020

Drug/Important Bio-Agent (IBA)

3	Endothelin Receptor AntagonistsIBA 12/2022 - 01/2020
3	aprocitentanIBA 12/2022 - 01/2020
2	Endothelins (Endothelin)IBA 12/2022 - 01/2020
1	Endothelin B ReceptorIBA 01/2020
1	Enalapril FDA LinkGeneric 09/2010
1	Renin InhibitorsIBA 09/2010
1	MK-8141IBA 09/2010